For: | Said A. Non-alcoholic fatty liver disease and liver transplantation: Outcomes and advances. World J Gastroenterol 2013; 19(48): 9146-9155 [PMID: 24409043 DOI: 10.3748/wjg.v19.i48.9146] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v19/i48/9146.htm |
Number | Citing Articles |
1 |
Hyeyoung Kim, Kwang‐Woong Lee, Kyoungbun Lee, Sooin Seo, Min‐Young Park, Sung Woo Ahn, Suk Kyun Hong, Kyung Chul Yoon, Hyo‐Sin Kim, YoungRok Choi, Hae Won Lee, Nam‐Joon Yi, Kyung‐Suk Suh. Effect of PNPLA3 I148M polymorphism on histologically proven non‐alcoholic fatty liver disease in liver transplant recipients. Hepatology Research 2018; 48(3) doi: 10.1111/hepr.12940
|
2 |
H. Jin, X. Xu, B. Pang, R. Yang, H. Sun, C. Jiang, D. Shao, J. Shi. Probiotic and prebiotic interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. Beneficial Microbes 2021; 12(6): 517 doi: 10.3920/BM2020.0183
|
3 |
|
4 |
Jeong Hee Yoon, Jeong Min Lee, Kyung-Suk Suh, Kwan-Woong Lee, Nam-Joon Yi, Kyung Bun Lee, Joon Koo Han, Byung Ihn Choi. Combined Use of MR Fat Quantification and MR Elastography in Living Liver Donors: Can It Reduce the Need for Preoperative Liver Biopsy?. Radiology 2015; 276(2): 453 doi: 10.1148/radiol.15140908
|
5 |
Sarina Pasricha, Jane Kenney-Hunt, Kristy Anderson, Nadereh Jafari, Rabea A Hall, Frank Lammert, James Cheverud, Richard M Green. Identification of eQTLs for Hepatic Xbp1s and Socs3 Gene Expression in Mice Fed a High-Fat, High-Caloric Diet. G3 Genes|Genomes|Genetics 2015; 5(4): 487 doi: 10.1534/g3.115.016626
|
6 |
Anchalia Chandrakumaran, Mohammad Shadab Siddiqui. Implications of Nonalcoholic Steatohepatitis as the Cause of End-Stage Liver Disease Before and After Liver Transplant. Gastroenterology Clinics of North America 2020; 49(1): 165 doi: 10.1016/j.gtc.2019.09.005
|
7 |
Ravikiran S. Karnam, Gopika Punchhi, Nicholas Mitsakakis, Shiyi Chen, Giovanna Saracino, Leslie Lilly, Sumeet K. Asrani, Mamatha Bhat. Predicting the outcome of liver transplantation in patients with non‐alcoholic steatohepatitis cirrhosis: The NASH LT risk‐benefit calculator. Clinical Transplantation 2023; 37(4) doi: 10.1111/ctr.14930
|
8 |
G. Losurdo, A. Castellaneta, M. Rendina, S. Carparelli, G. Leandro, A. Di Leo. Systematic review with meta‐analysis: de novo non‐alcoholic fatty liver disease in liver‐transplanted patients. Alimentary Pharmacology & Therapeutics 2018; 47(6): 704 doi: 10.1111/apt.14521
|
9 |
Varun Saxena, Norah A. Terrault. Zakim and Boyer's Hepatology. 2018; : 784 doi: 10.1016/B978-0-323-37591-7.00053-7
|
10 |
Hunter B. Moore, Yanik J. Bababekov, James J. Pomposelli, Megan A. Adams, Cara Crouch, Dor Yoeli, Rashikh A. Choudhury, Tanner Ferrell, James R. Burton, Elizabeth A. Pomfret, Trevor L. Nydam. The vexing triad of obesity, alcohol, and coagulopathy predicts the need for multiple operations in liver transplantation. The American Journal of Surgery 2022; 224(1): 69 doi: 10.1016/j.amjsurg.2022.02.053
|
11 |
Jennifer E. Lambert, Jill A. Parnell, Bertus Eksteen, Maitreyi Raman, Marc R. Bomhof, Kevin P. Rioux, Karen L. Madsen, Raylene A. Reimer. Gut microbiota manipulation with prebiotics in patients with non-alcoholic fatty liver disease: a randomized controlled trial protocol. BMC Gastroenterology 2015; 15(1) doi: 10.1186/s12876-015-0400-5
|
12 |
Giuseppina Pisano, Anna L Fracanzani, Lucio Caccamo, Maria F Donato, Silvia Fargion. Cardiovascular risk after orthotopic liver transplantation, a review of the literature and preliminary results of a prospective study. World Journal of Gastroenterology 2016; 22(40): 8869-8882 doi: 10.3748/wjg.v22.i40.8869
|
13 |
Ivana Mikolasevic, Lidija Orlic, Irena Hrstic, Sandra Milic. Metabolic syndrome and non‐alcoholic fatty liver disease after liver or kidney transplantation. Hepatology Research 2016; 46(9): 841 doi: 10.1111/hepr.12642
|
14 |
Hao-Jun Yang, Li-Ming Tang, Xian-Ju Zhou, Jun Qian, Jie Zhu, Ling Lu, Xue-Hao Wang. Ankaflavin ameliorates steatotic liver ischemia-reperfusion injury in mice. Hepatobiliary & Pancreatic Diseases International 2015; 14(6): 619 doi: 10.1016/S1499-3872(15)60361-7
|
15 |
Samer Gawrieh, Naga Chalasani. Alcoholic and Non-Alcoholic Fatty Liver Disease. 2016; : 313 doi: 10.1007/978-3-319-20538-0_16
|
16 |
Suliman Al Humayed. Protective and therapeutic effects ofCrataegus aroniain non-alcoholic fatty liver disease. Archives of Physiology and Biochemistry 2017; 123(1): 23 doi: 10.1080/13813455.2016.1205097
|
17 |
Kareem Hassan, Varun Bhalla, Mohammed Ezz El Regal, H Hesham A-Kader. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World Journal of Gastroenterology 2014; 20(34): 12082-12101 doi: 10.3748/wjg.v20.i34.12082
|
18 |
Xuanfei Li, Yakun Wu, Wenfeng Zhang, Jianping Gong, Yao Cheng. Pre-conditioning with tanshinone IIA attenuates the ischemia/reperfusion injury caused by liver grafts via regulation of HMGB1 in rat Kupffer cells. Biomedicine & Pharmacotherapy 2017; 89: 1392 doi: 10.1016/j.biopha.2017.03.022
|
19 |
Raquel G. Bardallo, Rui Teixeira da Silva, Teresa Carbonell, Emma Folch-Puy, Carlos Palmeira, Joan Roselló-Catafau, Jacques Pirenne, René Adam, Arnau Panisello-Roselló. Role of PEG35, Mitochondrial ALDH2, and Glutathione in Cold Fatty Liver Graft Preservation: An IGL-2 Approach. International Journal of Molecular Sciences 2021; 22(10): 5332 doi: 10.3390/ijms22105332
|
20 |
Conor P. Woods, Jonathon M. Hazlehurst, Jeremy W. Tomlinson. Glucocorticoids and non-alcoholic fatty liver disease. The Journal of Steroid Biochemistry and Molecular Biology 2015; 154: 94 doi: 10.1016/j.jsbmb.2015.07.020
|
21 |
Shuqian Wan, Long Zhang, Yunyun Quan, Kun Wei. Resveratrol-loaded PLGA nanoparticles: enhanced stability, solubility and bioactivity of resveratrol for non-alcoholic fatty liver disease therapy. Royal Society Open Science 2018; 5(11): 181457 doi: 10.1098/rsos.181457
|
22 |
Alabagi Abdulla, Charity Reynolds, H Hesham A-Kader. Non-Alcoholic Fatty Liver Disease (NAFLD): The Search for a Cure. European Medical Journal 2016; : 93 doi: 10.33590/emj/10314771
|
23 |
Xu Liu, Ayako Hakucho, Jinyao Liu, Tatsuya Fujimiya. Delayed ethanol elimination and enhanced susceptibility to ethanol-induced hepatosteatosis after liver resection. World Journal of Gastroenterology 2014; 20(48): 18249-18259 doi: 10.3748/wjg.v20.i48.18249
|
24 |
Maura O’Neil, Ivan Damjanov, Ryan M. Taylor. Liver Pathology for Clinicians. 2015; : 123 doi: 10.1007/978-3-319-20080-4_7
|
25 |
Qing Pang, Jing-Yao Zhang, Si-Dong Song, Kai Qu, Xin-Sen Xu, Su-Shun Liu, Chang Liu. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World Journal of Gastroenterology 2015; 21(5): 1650-1662 doi: 10.3748/wjg.v21.i5.1650
|
26 |
Antônio R. Andrade, Paulo L. Bittencourt, Liana Codes, Maria A. Evangelista, Alessandra O. Castro, Ney Boa Sorte, Carolina G. Almeida, Jorge A. Bastos, Helma P. Cotrim. New Onset Diabetes and Non-Alcoholic Fatty Liver Disease after Liver Transplantation. Annals of Hepatology 2017; 16(6): 932 doi: 10.5604/01.3001.0010.5285
|